Band purchase accelerates expansion of 300 billion Chinese medicine market "shuffle"

Pharmaceutical network August 19th, the State Health Insurance Bureau recently revealed that the relevant departments have held a symposium in mid-July, on biological products (including insulin) and traditional Chinese medicine centralized procurement work to listen to expert opinions and suggestions, research and improve the relevant areas of procurement policy, and promote procurement methods reform.
Industry insiders said that China's further expansion of the scope of centralized procurement signal is clear, although the Chinese medicine market compared with chemical drugs have their particularity, but it should be noted that the price of traditional Chinese medicine has been an inevitable trend, Traditional Chinese medicine is no exception.
In this context, full competition or the use of large varieties or take the lead in the inclusion of traditional Chinese medicine more than 300 billion yuan scale of the market or with the volume of procurement will officially enter the "shuffle" stage, the performance of traditional Chinese medicine enterprises will also be affected. more than
places have taken the lead in the pilot in late July, Qinghai Province drug and medical supplies centralized procurement network released Qinghai Province public medical institutions drug belt purchase bargain variety catalog and Qinghai Province public hospital drug belt purchase results, the results show that thrombosis injection, injection of blood plugs (freeze-dried), hi-inflammatory flat injections, blood plugs and other large varieties into the centralized belt purchase drug catalog.
, Zhejiang and Liaoning provinces have also piloted local versions of traditional Chinese medicine belt procurement.
June 8, Jinhua City, Zhejiang Province, issued the "announcement on the development of Jinhua City, the second batch of drug belt procurement" shows that the number of the current round of drug production procurement varieties as many as 274, involving a total procurement amount of 600 million yuan, of which 147 Traditional Chinese medicine (does not include low-cost drugs) And 33 traditional Chinese medicine (including low-cost medicine), including compound fishy herbal agent, oxen on the clear capsule, clearing the spirit particles, dredging detox capsules, ginseng injection, strong dew, thyme capsules, six-flavored yellow pills, ansan rehydration brain fluid and so on.
is worth noting that Jinhua City this band purchase synchronous clear payment policy.
the same negotiated variety of drugs in the same bidding group, the actual purchase price of the selected varieties as the standard of medical insurance payment.
medical institutions to implement zero-rate sales.
Medical institutions shall not settle drugs of the same selected variety that are higher than the medical insurance payment standard, and the co-ordination fund shall not settle the drug above the standard of medical insurance payment;
health insurance fixed-point pharmacies are sold at a price not exceeding 15% of the selected price.
In addition, regarding the quantity of procurement, Jinhua City clearly, by the relevant pharmaceutical institutions to estimate the estimated annual procurement volume for the following year, in principle, anti-infection drugs according to the previous year's use of 60% statistics;
for medicines that enter the procurement catalogue but are not selected by the enterprise, the member units of the Municipal Procurement Alliance are encouraged to select high-quality and low-cost alternative medicines.
at the same time, the un selected enterprise drug regulations in accordance with the previous year's use of 50% of the control use.
medical insurance agencies shall, within 1 month after the execution of the contract, advance 30% of the agreed procurement amount to the medical institutions as the turnover of the medical institutions.
the member units of the purchasing alliance in The City of China shall raise the rate of repayment and settle with the enterprise in a timely manner in accordance with the provisions of the agreement, and shall not exceed 45 days from the acceptance of receipt to payment.
July 22, Liaoning issued a notice on the development of drug invitation bidding and procurement work, further reform and improve the drug production and circulation of the use of policy, gas and blood oral liquid, Yunnan white medicine hemorrhoid paste, pediatric chai chai clear particles, joint analgesic babu paste, anti-ointment, etc. are in the recruitment list.
price drop is the "main theme" of price reduction is inevitable.
in Qinghai Province recently issued the volume of procurement requirements clearly, pharmaceutical enterprises should not be higher than the current national low procurement price, higher than the national low purchase price or as low as the current provincial procurement price is considered invalid tender.
Jinhua made it clear that anti-infection drugs are quoted separately according to the original and non-original drugs, and that the price reduction shall not be less than 10% based on the current standard of payment of medical insurance in Zhejiang Province (low-cost drugs at the linked (procurement) price).
a low-cost drug in the same generic name, the maximum price policy shall be adopted, and on the basis of the maximum price, the quotation shall not decrease by less than 10%.
industry insiders said, to chemical drug collection experience, once the collection policy is formally implemented, a significant reduction in drug prices will be inevitable.
he believes that once the selected varieties appear national to low prices, it will lead to a series of price cuts in the market, or will make the development of traditional Chinese medicine enterprises more difficult.
Jinhua City Health Insurance Bureau Director has publicly stated that Jinhua City's first batch of production procurement work has achieved good results, 22 drugs directly reduce the burden of patients 54 million yuan, an average decline of 28%, the highest drop of individual drugs up to 73.6%.
means that chinese medicines with special characteristics may start with more competitive medicines than chemicals.
, such as the production of thrombosis, blood plugcom, Shu Bloodining, ginseng wheat, wake-up call and other Chinese medicine injections enterprises may be the first to be affected.
meters in-network data show that traditional Chinese medicine covers 13 treatment categories, cardiovascular disease drugs for the Chinese traditional medicine market the first best-selling category, accounting for 35% of the market share, respiratory diseases accounted for 14.67 percent, skeletal muscle system drugs accounted for 8.58 percent.
specifically, in 2019 China's public medical institutions terminal chinese pharmaceutical products TOP20 cumulative sales reached 60.2 billion yuan, variety sales are more than 2 billion yuan, of which, injection thrombosis (freeze-dried) annual sales of up to 62.2 billion yuan 8.3 billion yuan, injection sales of dansan polyphenolates also reached 4.135 billion yuan, injection of blood plugs (freeze-dried) sales reached 3.928 billion yuan, Danhong injections 3.615 billion yuan.
the implementation of the purchase of large-scale belt, the decline in drug prices will have a significant impact on the production of these traditional Chinese medicine enterprises.
billion-level market "shuffle" on the one hand is the adjustment of the health insurance catalog, on the other hand, with the volume of procurement to accelerate the expansion of the market or will usher in a "shuffle" period.
, the overall growth rate of the Chinese traditional medicine market has continued to slow down due to the adjustment of medical insurance policy and the gradual refinement of hospital rational drug use policy. According to
meters in-network data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals and other public medical institutions terminal sales of traditional Chinese medicine sales of 283 billion yuan, the first time that the sales of traditional Chinese medicine showed a negative growth of 1.7%.
August 17, the State Health Insurance Administration announced the 2020 National Health Insurance Drug Catalog Adjustment Work Programme shows that drugs that have been revoked, revoked or cancelled by the State Drug Administration, taking into account clinical value, adverse reactions, drug economy and other factors, after assessment that the risk is greater than the benefits of drugs, will be directly excluded from the medical insurance catalog.
In addition, negotiated medicines that are within the validity period of the agreement and are subject to the agreement to redefine the payment criteria are significantly more expensive/expensive than other drugs in the same therapeutic field, and drugs that have taken up more funds in recent years will adjust the scope of payment and include eligible Chinese medicine tablets in the scope of the adjustment.
the same time, a new round of national procurement will be officially opened on August 20, the procurement involving 56 varieties, more than 80 specifications.
According to the announcement of the National Drug Centralized Procurement Document (GY-YD2020-1) issued by the Joint Procurement Office at the end of July, the agreed procurement volume for each variety in the first year shall be determined according to the following rules: the actual number of selected enterprises in the country is 1, and 50% of the base is calculated for the agreed procurement volume for the first year; The actual number of selected enterprises in the country is 2, which is 60% of the calculation base for the agreed purchase volume in the first year, 3 enterprises are selected in the first year, 70% of the base of the agreed procurement volume for the first year, and 80% of the base of the agreed purchase amount is calculated for the first year.
said that deepening the reform of centralized drug procurement and use, establishing a standardized and normal model of centralized drug belt procurement, and further reducing the burden of drug use by the masses are key work in the future.
the above-mentioned people pointed out that, according to statistics, the average price of drugs is generally dozens of times the cost of production, a large number of price moisture hidden in all aspects of drug circulation, many have become gray income.
because of the lack of strict management awareness, management can not be refined, many seemingly ordinary, "ant moving" type of behavior accumulated into more, causing serious erosion of health insurance funds.
" part of the traditional medicine also exists 'with gold sales'.
" the above-mentioned people admitted that some of the traditional chinese medicine often to cross-section, super-adaptation certificate and other means to promote, individual varieties of rebates even as high as 50%.
and volume procurement will further curb commercial bribery and continue to squeeze out drug price moisture.
therefore, the implementation of volume procurement is a challenge and an opportunity for Chinese traditional medicine enterprises.
Industry insiders said that price reduction, profit margins significantly reduced, Traditional Chinese medicine enterprises must have the determination to break their wrists, accelerate the transformation and upgrading, towards the direction of fine operation, and increase research and development of new drugs to further enhance the competitiveness of enterprises.
reporter Liang Wei.